ViroPharma to Present New HCV-796 to 13th in vitro data International Conference on Hepatitis C Virus-Related Virus
ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of new preclinical data on HCV-796, an orally dosed non nucleoside hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), at the 13th International Meeting on Hepatitis C virus related to Cairns, Australia.Quarter of 2006. These laboratory findings are very exciting and continue to support the observations of our clinical studies, ie, HCV-796 is an inhibitor of unique, potent and specific polymerase that, in terms of various HCV genotypes, and increases the antiviral effect of pegylated interferon, said Stephen Villano, MD, vice president of clinical research and development ViroPharma.
Inhibitors highlights the potential of
highly effective combination therapies for future treatment of this disease. The first set of data, reported in a poster presentation entitled Preclinical Characterization of non-nucleoside HCV polymerase-796, by Anita YM Howe et al. Demonstrate that HCV-796 is a specific inhibitor of HCV polymerase, and largely effective against HCV polymerases derived from different HCV genotypes, including genotypes 1a, 1b, 2, 3 and 4.measure the power of direct antiviral compounds for HCV, repeated exposure of replicon-containing cells to 1 uM HCV-796 for 16 days reduced HCV RNA levels by approximately 4 log10. The results of this study suggest that HCV-796 may interfere with the start of the event of RNA polymerization, which is the process by which HCV assembles its genetic structure
and is essential for the formation of infectious viral particles, consistent with studies of X-ray crystallographyalso observed in vitro in cells treated with HCV-796 pegylated interferon. The data presented in another poster, entitled Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, by Anita YM Howe et al. The conclusion that viral variants produced in vitro are
Pages: [1] 2 3